Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma.

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Blood

• Publication date

  2020-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.2020007994PMID 32932518PMCID PMC7907727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

  2020cited by this paper
• Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy

  2020cited by this paper
• Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

  2019cited by this paper
• Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

  2019cited by this paper
• Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

  2019cited by this paper
• First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

  2019cited by this paper
• Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

  2019cited by this paper
• Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration

  2019cited by this paper
• Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

  2019cited by this paper
• Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

  2018cited by this paper
• A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

  2018cited by this paper
• Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

  2018cited by this paper
• Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

  2018cited by this paper
• Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

  2017cited by this paper
• A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

  2017cited by this paper
• Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

  2017cited by this paper
• A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

  2017cited by this paper
• Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

  2014cited by this paper
• Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

  2014cited by this paper
• The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

  2014cited by this paper
• Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.

  2012cited by this paper
• Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

  2011cited by this paper
• Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

  2011cited by this paper
• Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.

  2010cited by this paper
• Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

  2010cited by this paper
• Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

  2009cited by this paper
• The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect

  2006cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper

• Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

  2025cites this paper
• A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma.

  2025cites this paper
• In pursuit of a functional cure for follicular lymphoma.

  2024cites this paper
• Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

  2024cites this paper
• Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203

  2024cites this paper
• Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy

  2024cites this paper
• Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

  2024cites this paper
• Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial.

  2023cites this paper
• SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

  2022cites this paper
• Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas

  2021cites this paper
• A SPECIAL MEETING REVIEW EDITION

  2021cites this paper
• Follicular lymphoma and macrophages: impact of approved and novel therapies

  2021cites this paper
• An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date

  2021cites this paper
• Highly-efficient production of spherical co-agglomerates of drugs via an organic solvent-free process and a mechanism study

  2021cites this paper
• DDDT_A_281614 3809..3820

  2021cites this paper